Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that CEO Kimberly Blackwell will participate in investor conferences. The 2022 Wells Fargo Healthcare Conference is set for September 7, 2022, at 2:35 p.m. ET in Boston, followed by the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:35 a.m. ET in New York City. Webcasts will be available on Zentalis' website.

As a clinical-stage biopharmaceutical firm, Zentalis focuses on small molecule therapies for cancer, with a diverse pipeline that includes potent candidates for various malignancies.

NEW YORK and SAN DIEGO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in fireside chats at two upcoming investor conferences.

Presentation Details:

Event: 2022 Wells Fargo Healthcare Conference
Date/Time: Wednesday, September 7th, 2022 at 2:35 p.m. ET
Location: Boston

Event: Morgan Stanley 20th Annual Global Healthcare Conference
Date/Time: Wednesday, September 14th, 2022 at 10:35 a.m. ET
Location: New York City

Webcasts will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. The Company has licensed ZN-c3, ZN-d5 and ZN-c5 to its joint venture, Zentera Therapeutics, Ltd. to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:

Alexandra Roy
Solebury Strategic Communications
aroy@soleburystrat.com

Media Contact:

Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystrat.com

FAQ

What is Zentalis Pharmaceuticals' stock symbol?

The stock symbol for Zentalis Pharmaceuticals is ZNTL.

When will Kimberly Blackwell speak at the Wells Fargo Healthcare Conference?

Kimberly Blackwell will speak at the Wells Fargo Healthcare Conference on September 7, 2022, at 2:35 p.m. ET.

What is the date and time for Zentalis' presentation at the Morgan Stanley Conference?

Zentalis will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:35 a.m. ET.

Where can I watch the webcasts of Zentalis Pharmaceuticals' conferences?

Webcasts can be accessed through the Investors section of Zentalis Pharmaceuticals' website.

What type of company is Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer.